VEGFA and neoplasm: Notwithstanding inherent limitations of subcutaneous cell line xenograft models, we have nevertheless recapitulated mCRC clinical response to combinatorial treatment when FOLFOX is delivered prior to anti-VEGF showing a significantly increased anti-tumour response for the TS2 sequence.